Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.70 |
| ▸ | TUBB | P07437 | 2/20 | 0.70 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.70 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.70 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.70 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.70 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.70 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.70 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.70 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.70 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.70 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.70 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.70 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.70 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7896500 | 0.92 | TUBB4A (0.61) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4464142 | 0.87 | HTR2A (0.75) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27456264 | 0.84 | TUBB4A (0.59) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9184918 | 0.82 | TUBB1 (0.73) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9189942 | 0.82 | TUBB4A (0.73) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL663128 | 0.82 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL7753304 | 0.82 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27560173 | 0.82 | ABCB1 (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6483085 | 0.81 | CYP19A1 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9089503 | 0.81 | TUBB4A (0.71) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410116-B2 | Compounds and use thereof in methods of treatment | THE UNIVERSITY OF QUEENSLAND (AU) | 2025-09-09 | — | — | US | disclosed |
| US-20240002326-A1 | COMPOUNDS AND USE THEREOF IN METHODS OF TREATMENT | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-01-04 | — | — | US | disclosed |
| US-20230100768-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-03-30 | — | — | US | disclosed |
| US-11434190-B2 | Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-09-06 | — | — | US | disclosed |
| CN-114573490-A | diaryl-2H-aziridines and diaryl aziridines compounds, preparation method and application thereof | 复旦大学 | 2022-06-03 | — | — | CN | disclosed |
| US-20190337880-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS-AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337880-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS-AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | SOX18, PROX1, RUNX1 | TUBB4A 1190/4885TUBB 1697/4885TUBA3C 3232/4885 |
| US-11434190-B2 | Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases | SOX18, PROX1, RUNX1 | TUBB4A 1190/4885TUBB 1697/4885TUBA3C 3232/4885 |
| US-20230100768-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | SOX18, PROX1, RUNX1 | TUBB4A 1240/4885TUBB 1858/4885TUBA3C 3375/4885 |
| US-12410116-B2 | Compounds and use thereof in methods of treatment | SOX18, PROX1, RUNX1 | TUBB4A 126/4885TUBB 198/4885TUBA3C 1068/4885 |
| US-20240002326-A1 | COMPOUNDS AND USE THEREOF IN METHODS OF TREATMENT | SOX18, PROX1, RUNX1 | TUBB4A 126/4885TUBB 198/4885TUBA3C 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.